Lson CV 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg and Clavulanic Acid 125 mg, designed to treat a broad spectrum of bacterial infections. Amoxycillin, a beta-lactam antibiotic, inhibits bacterial cell wall synthesis, leading to cell lysis and death. However, many bacteria produce beta-lactamase enzymes that inactivate amoxycillin, rendering it ineffective. Clavulanic Acid, a beta-lactamase inhibitor, protects amoxycillin from enzymatic degradation, thereby extending its antibacterial spectrum. Lson CV 625 is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, sinusitis, and dental infections caused by susceptible organisms. The combination is effective against beta-lactamase-producing strains of Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, Klebsiella species, and other pathogens. Dosage and duration should be determined by a healthcare professional based on infection severity and patient factors. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, with hypersensitivity reactions being less frequent but potentially serious. Caution is advised in patients with a history of penicillin allergy or hepatic impairment. Lson CV 625 Tablet should be used under medical supervision to ensure appropriate use and to minimize the risk of antibiotic resistance.